Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 4/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | FPR1 | P21462 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2764016 | 1.00 | MAPK1 (0.59) | MAPK1CYP2C19KDM1AMAOBADAMTS5 | |
| SCHEMBL15020639 | 1.00 | MAPK1 (0.59) | MAPK1CYP2C19KDM1AMAOBADAMTS5 | |
| SCHEMBL2764012 | 1.00 | MAPK1 (0.59) | MAPK1CYP2C19KDM1AMAOBADAMTS5 | |
| SCHEMBL14265357 | 1.00 | MAPK1 (0.59) | MAPK1CYP2C19KDM1AMAOBADAMTS5 | |
| SCHEMBL15116474 | 0.90 | MAPK1 (0.48) | MAPK1CYP2C19KDM1AMAOBADAMTS5 | |
| SCHEMBL15116668 | 0.90 | MAPK1 (0.48) | MAPK1CYP2C19KDM1AMAOBADAMTS5 | |
| SCHEMBL15116623 | 0.90 | MAPK1 (0.48) | MAPK1CYP2C19KDM1AMAOBADAMTS5 | |
| SCHEMBL14045956 | 0.90 | MAPK1 (0.48) | MAPK1CYP2C19KDM1AMAOBADAMTS5 | |
| SCHEMBL15116527 | 0.90 | MAPK1 (0.48) | MAPK1CYP2C19KDM1AMAOBADAMTS5 | |
| SCHEMBL9556579 | 0.89 | MAPK1 (0.47) | MAPK1CYP2C19KDM1AMAOBADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-115038688-A | USP30 inhibitors and uses thereof | 文森雷生物科学股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-4028385-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021050992-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| EP-3501546-A2 | CYSTEINE DRUG CONJUGATES AND USE OF SAME | Seattle Genetics, Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2621508-B1 | N-CARBOXYALKYL AURISTATINS AND THE USE THEREOF | SEATTLE GENETICS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20080306258-A1 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. | 2008-10-02 | — | — | US | disclosed |
| US-7351825-B2 | Cyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2005-10-06 | — | — | US | disclosed |
| WO-2005058884-A2 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058808-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | MMP13, MMP11, MMP3 | MAPK1 1144/4885CYP2C19 808/4885KDM1A 512/4885 |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | MAPK1 3049/4885CYP2C19 4289/4885KDM1A 3254/4885 |
| US-20080261994-A1 | CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MMP13, MMP9, MMP11 | MAPK1 2090/4885CYP2C19 159/4885KDM1A 1248/4885 |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | MMP13, MMP11, MMP1 | MAPK1 1083/4885CYP2C19 755/4885KDM1A 477/4885 |
| US-20080306258-A1 | Cyclopropane compounds and pharmaceutical use thereof | MMP13, MMP9, MMP11 | MAPK1 2078/4885CYP2C19 170/4885KDM1A 1163/4885 |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | DDR1, IGFBP6, KDR | MAPK1 2248/4885CYP2C19 4665/4885KDM1A 3109/4885 |
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | MAPK1 2205/4885CYP2C19 4475/4885KDM1A 310/4885 |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | MAPK1 2205/4885CYP2C19 4475/4885KDM1A 310/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | MAPK1 2205/4885CYP2C19 4475/4885KDM1A 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.